UK-based inflammatory disease and cancer specialist Karus Therapeutics has appointed Simon Roitt as head of clinical development and Peter Finan as head of biology.
Dr Roitt joined Karus in August with 20 years of clinical development experience in healthcare. He has previously worked at Roche and GE Healthcare.
Dr Finan has held positions in pharma from target discovery through to early clinical development in oncology and inflammatory disease. He joins from Novartis, where he worked in various positions for 16 years.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze